GenMark Diagnostics, Inc.
Oct 22, 2012

GenMark to Show its All-Electronic, Sample-to-Answer Molecular Diagnostics Platform at the Association for Molecular Pathology Meeting

CARLSBAD, Calif.--(BUSINESS WIRE)-- GenMark Diagnostics Inc., (NASDAQ: GNMK) a leading provider of automated, multiplex molecular diagnostic testing systems, announced today that it will show a prototype of the Company's NexGen system, an all-electronic fully integrated molecular diagnostics platform, at the Association of Molecular Pathology (AMP) meeting to be held on October 25-27, 2012 in Long Beach, California.

The NexGen platform is a multiplex sample-to-answer system which integrates sample preparation steps including extraction and amplification, together with the company's proprietary electrochemical detection technology, to enable concurrent detection of multiple molecular targets on a single test cartridge. All necessary reagents are fully incorporated in self-contained test cartridges, with the required fluidic movement enabled by proprietary digital microfluidics technology licensed by the Company earlier this year.

GenMark is also developing an extensive test menu for the NexGen platform which covers a broad range of disease states. With an initial focus on infectious disease, the Company will target both multiplex and less complex test panels where current platform and menu options are very limited. Future NexGen menu will also include test panels for pharmacogenetic, oncology and genetic testing.

"The demonstration of our prototype NexGen system at AMP is a significant milestone which highlights the continued progress of our product development program and supports our goal of commercial launch in late 2013," commented Hany Massarany, President and CEO of GenMark Diagnostics. "The revolutionary and proprietary combination of electronic detection and digital microfluidics underpins the unique value proposition of our all-digital sample-to-answer NexGen system; a system we believe will redefine industry standards for performance, reliability and ease of use even with the most complex assays."

For more information regarding the AMP showing of the GenMark NexGen platform, investors should contact GenMark Diagnostics at (760) 448-4358.

About GenMark Diagnostics, Inc.

GenMark Diagnostics is a leading provider of automated, multiplex molecular diagnostic testing systems that detect and measure DNA and RNA targets to diagnose disease and optimize patient treatment. Utilizing GenMark's proprietary eSensor® detection technology, GenMark's eSensor® XT-8 system is designed to support a broad range of molecular diagnostic tests with a compact, easy-to-use workstation and self-contained, disposable test cartridges. GenMark currently markets four tests that are FDA cleared for IVD use: Cystic Fibrosis Genotyping Test, Respiratory Virus Panel, Thrombophilia Risk Test, and Warfarin Sensitivity Test. A number of other tests, including HCV Genotyping and 2C19 are in development. For more information, visit

Safe Harbor Statement

This press release includes forward-looking statements regarding events, trends and business prospects, which may affect our future operating results and financial position. Such statements, including, but not limited to, those regarding our growth strategy, are all subject to risks and uncertainties that could cause our actual results and financial position to differ materially. Some of these risks and uncertainties include, but are not limited to, our research and development plans and timelines, risks related to our history of operating losses, the need for further financing and our ability to access the necessary additional capital for our business, inherent risk and uncertainty in the protection intellectual property rights, and regulatory uncertainties regarding approval or clearance for our products, as well as other risks and uncertainties described under the "Risk Factors" in our public filings with the Securities and Exchange Commission. We assume no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made.

GenMark Diagnostics Inc.
Hany Massarany
Chief Executive Officer

Source: GenMark Diagnostics Inc.

News Provided by Acquire Media